Millennium Ranked In Top 10 Biotech / Biopharmaceutical Companies For 5th Consecutive Year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today announced that Science magazine has named it among the best biopharmaceutical employers in the world for the fifth consecutive year. Each year Science conducts a survey to determine the top employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries worldwide. In this year’s survey results, Millennium was ranked number 6. This is the fifth consecutive year that Millennium has been in the top ten.

“Being ranked in the top ten places to work for the fifth consecutive year by Science reinforces Millennium’s commitment to our employees, our unique culture and innovative science”

“Being ranked in the top ten places to work for the fifth consecutive year by Science reinforces Millennium’s commitment to our employees, our unique culture and innovative science,” said Stephen Gansler, Senior Vice President, Human Resources, Millennium. “Now, more than ever, it’s important for Millennium to maintain our diverse and positive working environment as we strive to develop innovative medicines that will make a difference in the lives of patients around the world.”

Respondents to the web-based survey were asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change and research-driven environment. The 2012 survey sought to identify the companies with the best reputations as employers based on 4,276 survey responses from readers of Science and other survey invitees. Approximately 20 percent of survey participants came from outside North America. Survey results were independently analyzed by The Brighton Consulting Group. To read the complete article appearing in the September 21, 2012 issue of Science with individual company rankings, please visit: www.sciencecareers.org/TopEmployers2012.

About Millennium

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.

Editors’ Note: This press release is also available under the Media section of the Company’s website at: http://www.millennium.com/.